Details for: IGF2R
Gene ID: 3482
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: IGF2R
Ensembl ID: ENSG00000197081
Description: insulin like growth factor 2 receptor
Selected Context(s): Overall
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 16.4rCSI 25.06%PRS 31.84
-
CSI 15.62rCSI 41.45%PRS 37.12
-
CSI 13.34rCSI 12.31%PRS 25.69
-
CSI 8.76rCSI 17.58%PRS 18.21
-
CSI 8.66rCSI 12.35%PRS 27.39
-
CSI 8.51rCSI 31.87%PRS 20.64
-
CSI 6.87rCSI 15.65%PRS 25.13
-
CSI 6.86rCSI 24.7%PRS 13.95
-
CSI 6.75rCSI 15.08%PRS 28.89
-
CSI 6.36rCSI 8.84%PRS 24.89
-
CSI 6.28rCSI 11.23%PRS 22.8
-
CSI 6.18rCSI 5.95%PRS 25.48
-
CSI 5.83rCSI 8.25%PRS 34.1
-
CSI 5.73rCSI 13.99%PRS 23.74
-
CSI 5.63rCSI 8.98%PRS 20.92
-
CSI 5.38rCSI 6.32%PRS 28.14
-
CSI 5.07rCSI 8.15%PRS 18.84
-
CSI 5.01rCSI 6.24%PRS 13.85
-
CSI 4.99rCSI 7.32%PRS 32.09
-
CSI 4.94rCSI 7.86%PRS 20.69
-
CSI 4.91rCSI 26.84%PRS 35.19
-
CSI 4.86rCSI 17.28%PRS 64.82
-
CSI 4.72rCSI 38.35%PRS 23.58
-
CSI 4.17rCSI 7.95%PRS 38.29
-
CSI 4.1rCSI 10.37%PRS 30.18
-
CSI 3.94rCSI 2.74%PRS 29.69
-
CSI 3.93rCSI 2.95%PRS 26.34
-
CSI 3.88rCSI 3.14%PRS 36.35
-
CSI 3.88rCSI 6.25%PRS 36
-
CSI 3.8rCSI 5.39%PRS 22.79
-
CSI 3.75rCSI 11.12%PRS 33.8
-
CSI 3.72rCSI 5.61%PRS 25.17
-
CSI 3.53rCSI 4.69%PRS 26.99
-
CSI 3.33rCSI 14.65%PRS 22.33
-
CSI 3.32rCSI 7.28%PRS 32.48
-
CSI 3.25rCSI 2.85%PRS 32.41
-
CSI 3.23rCSI 5.67%PRS 18.92
-
CSI 3.05rCSI 3.13%PRS 43.26
-
CSI 3.03rCSI 2.8%PRS 43.22
-
CSI 2.96rCSI 1.75%PRS 34.65
-
CSI 2.94rCSI 4.52%PRS 32.11
-
CSI 2.85rCSI 4.08%PRS 32.52
-
CSI 2.82rCSI 3.59%PRS 28.33
-
CSI 2.8rCSI 2.6%PRS 24.57
-
CSI 2.77rCSI 8.87%PRS 20.44
-
CSI 2.76rCSI 1.84%PRS 53.93
-
CSI 2.73rCSI 2.12%PRS 36.07
-
CSI 2.72rCSI 23.53%PRS 33.96
-
CSI 2.6rCSI 3.55%PRS 27.25
-
CSI 2.57rCSI 1.91%PRS 21.11
-
CSI 2.57rCSI 2.52%PRS 37.82
-
CSI 2.54rCSI 2.66%PRS 22.96
-
CSI 2.51rCSI 4%PRS 26.91
-
CSI 2.47rCSI 5.89%PRS 27.45
-
CSI 2.47rCSI 11.41%PRS 47.93
-
CSI 2.44rCSI 2.22%PRS 37.06
-
CSI 2.43rCSI 5.46%PRS 45.49
-
CSI 2.4rCSI 1.72%PRS 33.78
-
CSI 2.37rCSI 2.06%PRS 31.11
-
CSI 2.35rCSI 3.45%PRS 22.67
-
CSI 2.32rCSI 2.81%PRS 29.69
-
CSI 2.32rCSI 6.79%PRS 61.39
-
CSI 2.32rCSI 2.42%PRS 25.17
-
CSI 2.26rCSI 1.58%PRS 34.56
-
CSI 2.21rCSI 2.7%PRS 30.55
-
CSI 2.2rCSI 3.01%PRS 27.71
-
CSI 2.2rCSI 8.89%PRS 22.79
-
CSI 2.2rCSI 1.53%PRS 26.26
-
CSI 2.17rCSI 1.93%PRS 24.83
-
CSI 2.16rCSI 4.29%PRS 25.48
-
CSI 2.12rCSI 3.1%PRS 26.08
-
CSI 2.11rCSI 9.66%PRS 51.25
-
CSI 2.1rCSI 1.66%PRS 16.91
-
CSI 2.09rCSI 3.92%PRS 17.87
-
CSI 2.09rCSI 2.86%PRS 45.53
-
CSI 2.07rCSI 2.42%PRS 34.5
-
CSI 2.04rCSI 1.58%PRS 23.82
-
CSI 2.03rCSI 4.65%PRS 24.03
-
CSI 1.99rCSI 6.75%PRS 24.36
-
CSI 1.98rCSI 2.54%PRS 23.69
-
CSI 1.92rCSI 4.5%PRS 34.39
-
CSI 1.91rCSI 7.39%PRS 45.07
-
CSI 1.9rCSI 2.21%PRS 34.94
-
CSI 1.9rCSI 1.44%PRS 32.63
-
CSI 1.88rCSI 2.02%PRS 22.65
-
CSI 1.88rCSI 1.26%PRS 30.59
-
CSI 1.87rCSI 4.63%PRS 22.86
-
CSI 1.84rCSI 3.73%PRS 13.34
-
CSI 1.84rCSI 2.5%PRS 21.5
-
CSI 1.83rCSI 2.35%PRS 28.31
-
CSI 1.83rCSI 2.11%PRS 21.3
-
CSI 1.83rCSI 3%PRS 18.97
-
CSI 1.82rCSI 1.48%PRS 25.71
-
CSI 1.81rCSI 10.41%PRS 29.99
-
CSI 1.79rCSI 4.55%PRS 24.22
-
CSI 1.79rCSI 4.14%PRS 19.84
-
CSI 1.78rCSI 1.47%PRS 23.36
-
CSI 1.77rCSI 2.2%PRS 33.87
-
CSI 1.76rCSI 1.67%PRS 25.79
-
CSI 1.72rCSI 2.47%PRS 19.16
-
CSI 0.1rCSI 0.8%PRS 35.9%
-
CSI 0.2rCSI 4.9%PRS 20.3%
-
CSI 0.2rCSI 4.9%PRS 21.5%
-
CSI 0.3rCSI 0.5%PRS 31.5%
-
CSI 0.3rCSI 3.6%PRS 66.8%
-
CSI 0.4rCSI 2.2%PRS 35.6%
-
CSI 0.4rCSI 2.3%PRS 50.8%
-
CSI 0.4rCSI 2.9%PRS 15.4%
-
CSI 0.4rCSI 9.3%PRS 44.7%
-
CSI 0.4rCSI 3.0%PRS 43.6%
-
CSI 0.4rCSI 0.4%PRS 18.0%
-
CSI 0.4rCSI 5.9%PRS 19.6%
-
CSI 0.5rCSI 2.3%PRS 33.0%
-
CSI 0.5rCSI 1.7%PRS 38.9%
-
CSI 0.5rCSI 1.2%PRS 30.6%
-
CSI 0.5rCSI 5.5%PRS 41.8%
-
CSI 0.5rCSI 3.1%PRS 15.5%
-
CSI 0.6rCSI 1.0%PRS 14.6%
-
CSI 0.6rCSI 2.3%PRS 23.1%
-
CSI 0.6rCSI 2.7%PRS 23.9%
-
CSI 0.6rCSI 2.0%PRS 15.6%
-
CSI 0.7rCSI 3.2%PRS 55.0%
-
CSI 0.7rCSI 2.8%PRS 40.5%
-
CSI 0.7rCSI 1.9%PRS 31.8%
-
CSI 0.7rCSI 1.1%PRS 23.0%
-
CSI 0.7rCSI 1.4%PRS 31.3%
-
CSI 0.7rCSI 2.4%PRS 17.7%
-
CSI 0.7rCSI 1.7%PRS 36.0%
-
CSI 0.7rCSI 1.1%PRS 39.2%
-
CSI 0.8rCSI 2.2%PRS 19.2%
-
CSI 0.8rCSI 2.2%PRS 37.5%
-
CSI 0.8rCSI 2.2%PRS 30.8%
-
CSI 0.8rCSI 2.1%PRS 18.7%
-
CSI 0.8rCSI 1.4%PRS 33.1%
-
CSI 0.8rCSI 3.8%PRS 45.7%
-
CSI 0.8rCSI 1.3%PRS 24.7%
-
CSI 0.8rCSI 1.1%PRS 34.8%
-
CSI 0.8rCSI 3.9%PRS 50.2%
-
CSI 0.9rCSI 4.1%PRS 29.3%
-
CSI 0.9rCSI 2.0%PRS 17.6%
-
CSI 0.9rCSI 1.8%PRS 35.1%
-
CSI 0.9rCSI 4.3%PRS 20.6%
-
CSI 0.9rCSI 2.7%PRS 27.5%
-
CSI 0.9rCSI 2.2%PRS 16.8%
-
CSI 1.0rCSI 1.4%PRS 22.7%
-
CSI 1.0rCSI 10.1%PRS 30.2%
-
CSI 1.0rCSI 2.0%PRS 23.5%
-
CSI 1.0rCSI 2.6%PRS 20.4%
-
CSI 1.0rCSI 2.9%PRS 36.9%
-
CSI 1.0rCSI 2.6%PRS 22.8%
-
CSI 1.0rCSI 2.0%PRS 25.3%
-
CSI 1.0rCSI 3.3%PRS 29.2%
-
CSI 1.0rCSI 2.9%PRS 27.0%
-
CSI 1.0rCSI 17.4%PRS 67.4%
-
CSI 1.1rCSI 2.9%PRS 22.9%
-
CSI 1.1rCSI 1.8%PRS 28.9%
-
CSI 1.1rCSI 2.6%PRS 35.8%
-
CSI 1.1rCSI 2.6%PRS 30.0%
-
CSI 1.1rCSI 1.1%PRS 21.1%
-
CSI 1.1rCSI 3.6%PRS 25.3%
-
CSI 1.1rCSI 1.2%PRS 25.5%
-
CSI 1.1rCSI 5.7%PRS 32.5%
-
CSI 1.2rCSI 3.2%PRS 39.4%
-
CSI 1.2rCSI 4.7%PRS 34.5%
-
CSI 1.2rCSI 2.0%PRS 14.8%
-
CSI 1.2rCSI 2.1%PRS 31.6%
-
CSI 1.2rCSI 2.9%PRS 35.2%
-
CSI 1.2rCSI 1.5%PRS 41.9%
-
CSI 1.3rCSI 2.7%PRS 36.6%
-
CSI 1.3rCSI 2.9%PRS 45.5%
-
CSI 1.3rCSI 1.0%PRS 23.1%
-
CSI 1.3rCSI 2.8%PRS 22.7%
-
CSI 1.3rCSI 2.8%PRS 15.4%
-
CSI 1.3rCSI 1.3%PRS 26.1%
-
CSI 1.3rCSI 7.7%PRS 40.8%
-
CSI 1.3rCSI 3.4%PRS 23.1%
-
CSI 1.3rCSI 1.9%PRS 27.5%
-
CSI 1.3rCSI 1.3%PRS 26.4%
-
CSI 1.3rCSI 3.8%PRS 41.7%
-
CSI 1.3rCSI 2.0%PRS 24.7%
-
CSI 1.4rCSI 5.1%PRS 15.3%
-
CSI 1.4rCSI 3.3%PRS 14.5%
-
CSI 1.4rCSI 33.4%PRS 14.4%
-
CSI 1.4rCSI 1.5%PRS 29.1%
-
CSI 1.4rCSI 1.9%PRS 26.7%
-
CSI 1.4rCSI 2.5%PRS 18.8%
-
CSI 1.4rCSI 1.7%PRS 41.7%
-
CSI 1.4rCSI 3.2%PRS 28.1%
-
CSI 1.4rCSI 3.8%PRS 29.3%
-
CSI 1.5rCSI 34.8%PRS 13.5%
-
CSI 1.5rCSI 1.9%PRS 15.4%
-
CSI 1.5rCSI 1.8%PRS 26.3%
-
CSI 1.5rCSI 1.7%PRS 18.2%
-
CSI 1.5rCSI 2.4%PRS 16.1%
-
CSI 1.5rCSI 4.6%PRS 35.6%
-
CSI 1.5rCSI 1.3%PRS 29.1%
-
CSI 1.5rCSI 2.3%PRS 28.1%
-
CSI 1.5rCSI 4.7%PRS 16.9%
-
CSI 1.5rCSI 2.8%PRS 49.2%
-
CSI 1.5rCSI 9.4%PRS 19.4%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 2275761246
Symbol: MPRI_HUMAN
Name: Cation-independent mannose-6-phosphate receptor
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 2957598
Title: Insulin-like growth factor II receptor as a multifunctional binding protein.
PubMed ID: 2957598
DOI: 10.1038/329301a0
PubMed ID: 2963003
Title: The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells.
PubMed ID: 2963003
PubMed ID: 9892739
Title: Genomic structure of the human M6P/IGF2 receptor.
PubMed ID: 9892739
PubMed ID: 14574404
Title: The DNA sequence and analysis of human chromosome 6.
PubMed ID: 14574404
DOI: 10.1038/nature02055
PubMed ID: 10900005
Title: Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation.
PubMed ID: 10900005
PubMed ID: 11387475
Title: Sorting of mannose 6-phosphate receptors mediated by the GGAs.
PubMed ID: 11387475
PubMed ID: 12754519
Title: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.
PubMed ID: 12754519
DOI: 10.1038/nbt827
PubMed ID: 17081983
Title: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
PubMed ID: 17081983
PubMed ID: 17487921
Title: Toward a global characterization of the phosphoproteome in prostate cancer cells: identification of phosphoproteins in the LNCaP cell line.
PubMed ID: 17487921
PubMed ID: 18220336
Title: Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.
PubMed ID: 18220336
DOI: 10.1021/pr0705441
PubMed ID: 19367720
Title: Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment.
PubMed ID: 19367720
DOI: 10.1021/pr800500r
PubMed ID: 18691976
Title: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
PubMed ID: 18691976
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 18318008
Title: Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography.
PubMed ID: 18318008
PubMed ID: 18817523
Title: Palmitoylation controls recycling in lysosomal sorting and trafficking.
PubMed ID: 18817523
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19159218
Title: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.
PubMed ID: 19159218
DOI: 10.1021/pr8008012
PubMed ID: 19369195
Title: Large-scale proteomics analysis of the human kinome.
PubMed ID: 19369195
PubMed ID: 19690332
Title: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
PubMed ID: 19690332
PubMed ID: 19608861
Title: Lysine acetylation targets protein complexes and co-regulates major cellular functions.
PubMed ID: 19608861
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 21406692
Title: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
PubMed ID: 21406692
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 25944712
Title: N-terminome analysis of the human mitochondrial proteome.
PubMed ID: 25944712
PubMed ID: 18046459
Title: Structure and functional analysis of the IGF-II/IGF2R interaction.
PubMed ID: 18046459
Sequence Information:
- Length: 2491
- Mass: 274375
- Checksum: 3841ADE559B48057
- Sequence:
MGAAAGRSPH LGPAPARRPQ RSLLLLQLLL LVAAPGSTQA QAAPFPELCS YTWEAVDTKN NVLYKINICG SVDIVQCGPS SAVCMHDLKT RTYHSVGDSV LRSATRSLLE FNTTVSCDQQ GTNHRVQSSI AFLCGKTLGT PEFVTATECV HYFEWRTTAA CKKDIFKANK EVPCYVFDEE LRKHDLNPLI KLSGAYLVDD SDPDTSLFIN VCRDIDTLRD PGSQLRACPP GTAACLVRGH QAFDVGQPRD GLKLVRKDRL VLSYVREEAG KLDFCDGHSP AVTITFVCPS ERREGTIPKL TAKSNCRYEI EWITEYACHR DYLESKTCSL SGEQQDVSID LTPLAQSGGS SYISDGKEYL FYLNVCGETE IQFCNKKQAA VCQVKKSDTS QVKAAGRYHN QTLRYSDGDL TLIYFGGDEC SSGFQRMSVI NFECNKTAGN DGKGTPVFTG EVDCTYFFTW DTEYACVKEK EDLLCGATDG KKRYDLSALV RHAEPEQNWE AVDGSQTETE KKHFFINICH RVLQEGKARG CPEDAAVCAV DKNGSKNLGK FISSPMKEKG NIQLSYSDGD DCGHGKKIKT NITLVCKPGD LESAPVLRTS GEGGCFYEFE WHTAAACVLS KTEGENCTVF DSQAGFSFDL SPLTKKNGAY KVETKKYDFY INVCGPVSVS PCQPDSGACQ VAKSDEKTWN LGLSNAKLSY YDGMIQLNYR GGTPYNNERH TPRATLITFL CDRDAGVGFP EYQEEDNSTY NFRWYTSYAC PEEPLECVVT DPSTLEQYDL SSLAKSEGGL GGNWYAMDNS GEHVTWRKYY INVCRPLNPV PGCNRYASAC QMKYEKDQGS FTEVVSISNL GMAKTGPVVE DSGSLLLEYV NGSACTTSDG RQTTYTTRIH LVCSRGRLNS HPIFSLNWEC VVSFLWNTEA ACPIQTTTDT DQACSIRDPN SGFVFNLNPL NSSQGYNVSG IGKIFMFNVC GTMPVCGTIL GKPASGCEAE TQTEELKNWK PARPVGIEKS LQLSTEGFIT LTYKGPLSAK GTADAFIVRF VCNDDVYSGP LKFLHQDIDS GQGIRNTYFE FETALACVPS PVDCQVTDLA GNEYDLTGLS TVRKPWTAVD TSVDGRKRTF YLSVCNPLPY IPGCQGSAVG SCLVSEGNSW NLGVVQMSPQ AAANGSLSIM YVNGDKCGNQ RFSTRITFEC AQISGSPAFQ LQDGCEYVFI WRTVEACPVV RVEGDNCEVK DPRHGNLYDL KPLGLNDTIV SAGEYTYYFR VCGKLSSDVC PTSDKSKVVS SCQEKREPQG FHKVAGLLTQ KLTYENGLLK MNFTGGDTCH KVYQRSTAIF FYCDRGTQRP VFLKETSDCS YLFEWRTQYA CPPFDLTECS FKDGAGNSFD LSSLSRYSDN WEAITGTGDP EHYLINVCKS LAPQAGTEPC PPEAAACLLG GSKPVNLGRV RDGPQWRDGI IVLKYVDGDL CPDGIRKKST TIRFTCSESQ VNSRPMFISA VEDCEYTFAW PTATACPMKS NEHDDCQVTN PSTGHLFDLS SLSGRAGFTA AYSEKGLVYM SICGENENCP PGVGACFGQT RISVGKANKR LRYVDQVLQL VYKDGSPCPS KSGLSYKSVI SFVCRPEARP TNRPMLISLD KQTCTLFFSW HTPLACEQAT ECSVRNGSSI VDLSPLIHRT GGYEAYDESE DDASDTNPDF YINICQPLNP MHGVPCPAGA AVCKVPIDGP PIDIGRVAGP PILNPIANEI YLNFESSTPC LADKHFNYTS LIAFHCKRGV SMGTPKLLRT SECDFVFEWE TPVVCPDEVR MDGCTLTDEQ LLYSFNLSSL STSTFKVTRD SRTYSVGVCT FAVGPEQGGC KDGGVCLLSG TKGASFGRLQ SMKLDYRHQD EAVVLSYVNG DRCPPETDDG VPCVFPFIFN GKSYEECIIE SRAKLWCSTT ADYDRDHEWG FCRHSNSYRT SSIIFKCDED EDIGRPQVFS EVRGCDVTFE WKTKVVCPPK KLECKFVQKH KTYDLRLLSS LTGSWSLVHN GVSYYINLCQ KIYKGPLGCS ERASICRRTT TGDVQVLGLV HTQKLGVIGD KVVVTYSKGY PCGGNKTASS VIELTCTKTV GRPAFKRFDI DSCTYYFSWD SRAACAVKPQ EVQMVNGTIT NPINGKSFSL GDIYFKLFRA SGDMRTNGDN YLYEIQLSSI TSSRNPACSG ANICQVKPND QHFSRKVGTS DKTKYYLQDG DLDVVFASSS KCGKDKTKSV SSTIFFHCDP LVEDGIPEFS HETADCQYLF SWYTSAVCPL GVGFDSENPG DDGQMHKGLS ERSQAVGAVL SLLLVALTCC LLALLLYKKE RRETVISKLT TCCRRSSNVS YKYSKVNKEE ETDENETEWL MEEIQLPPPR QGKEGQENGH ITTKSVKALS SLHGDDQDSE DEVLTIPEVK VHSGRGAGAE SSHPVRNAQS NALQEREDDR VGLVRGEKAR KGKSSSAQQK TVSSTKLVSF HDDSDEDLLH I